Myasthenia Gravis - Pipeline Review, Q4 2010

Date: November 1, 2010
Pages: 50
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: M85BE2E2F5AEN
Leaflet:

Download PDF Leaflet

Myasthenia Gravis - Pipeline Review, Q4 2010
Summary

Global Markets Direct’s, “Myasthenia Gravis Pipeline Review 2010, Q4 2010”, provides an overview into the Myasthenia Gravis therapeutic pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Myasthenia Gravis. “Myasthenia Gravis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company/University’s website, SEC filings, investor presentations and featured press releases, both from company/university sites and industry-specific third party sources, put together with in-house assessment, by Global Markets Direct’s team of industry experts.

Scope

- A snapshot of the global therapeutic scenario for Myasthenia Gravis.
- Review of the Myasthenia Gravis pipeline products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Includes pipeline products based on various stages of development ranging from discovery till registration stages.
- Includes pipeline projects on the basis of monotherapy and combined therapeutics.
- Study of the Myasthenia Gravis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand various therapeutics under development for Myasthenia Gravis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Get an insight into important and diverse types of therapeutics in pipeline for Myasthenia Gravis and understand the trends and players likely to impact the global Myasthenia Gravis market in future.
- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus and the future of Myasthenia Gravis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
- Avoid Intellectual Property Rights related issues.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION

2.1 Global Markets Direct Report Coverage

3 INTRODUCTION

3.1 About Myasthenia Gravis
3.2 An Overview of Myasthenia Gravis Therapeutics

4 MYASTHENIA GRAVIS THERAPEUTICS DEVELOPMENT

4.1 An Overview of Pipeline Products for Myasthenia Gravis
4.2 Myasthenia Gravis Therapeutics under Development by Companies
4.3 Myasthenia Gravis Therapeutics under Investigation by Universities/Institutes
4.4 Late Clinical Stage Products
  4.4.1 Comparative Analysis
  4.4.2 Late Clinical Stage Products - Companies
  4.4.3 Late Clinical Stage Products - Universities/Institutes
4.5 Mid Clinical Stage Products
  4.5.1 Comparative Analysis
  4.5.2 Mid Clinical Stage Products - Companies
  4.5.3 Mid Clinical Stage Products - Universities/Institutes
4.6 Early Clinical Stage Products
  4.6.1 Comparative Analysis
  4.6.2 Early Clinical Stage Products - Companies
  4.6.3 Early Clinical Stage Products - Universities/Institutes
4.7 Pre-clinical and Discovery Stage Products
  4.7.1 Comparative Analysis
  4.7.2 Pre-clinical and Discovery Stage Products - Companies

5 COMPANIES INVOLVED IN MYASTHENIA GRAVIS THERAPEUTICS DEVELOPMENT
6 UNIVERSITIES/INSTITUTES INVOLVED IN MYASTHENIA GRAVIS THERAPEUTICS DEVELOPMENT
7 MYASTHENIA GRAVIS THERAPEUTICS ASSESSMENT

7.1 Assessment by Monotherapy Products
7.2 Assessment by Combined Therapeutics
7.3 Assessment by Therapeutic Class
7.4 Assessment by Route of Administration
7.5 Assessment by Molecule Type
  7.5.1 Assessment by Biologics/Non-Biologics under Development

8 LATE STAGE DRUG PROFILES – COMPANY

8.1 Drug 1 Profile
  8.1.1 Product Description
  8.1.2 Mechanism of Action
  8.1.3 R&D Progress

9 LATE STAGE DRUG PROFILES – UNIVERSITIES/INSTITUTES

9.1 Drug 1 Profile
  9.1.1 Product Description
  9.1.2 Mechanism of Action
  9.1.3 R&D Progress

10 MYASTHENIA GRAVIS THERAPEUTICS - DISCONTINUED COMPANY PRODUCTS
11 MYASTHENIA GRAVIS THERAPEUTICS – FEATURED NEWS
12 APPENDIX

12.1 Research Methodology
12.2 Secondary Research
12.3 Global Markets Direct Consulting
12.4 Contact Us
12.5 Disclaimer

LIST OF TABLES

Table 1: Number of Products under Development,
Table 2: Myasthenia Gravis Products under Development – Comparative Analysis,
Table 3: Number of Products under Development by Companies,
Table 4: Number of Products under Investigation by Universities/Institutes,
Table 5: Comparative Analysis by Late Clinical Stage Development,
Table 6: Late Clinical Stage Products – Companies,
Table 7: Late Clinical Stage Products - Universities/Institutes,
Table 8: Comparative Analysis by Mid Clinical Stage Development,
Table 9: Mid Clinical Stage Products - Companies,
Table 10: Mid Clinical Stage Products - Universities/Institutes,
Table 11: Comparative Analysis by Early Clinical Stage Development,
Table 12: Early Clinical Stage Products - Companies,
Table 13: Early Clinical Stage Products - Universities/Institutes,
Table 14: Comparative Analysis by Pre-clinical and Discovery Stage Development,
Table 15: Pre-clinical and Discovery Stage Products - Companies,
Table 16: Companies Involved in Myasthenia Gravis Therapeutics Development - Company
Table 17: Products under Investigation by Universities/Institutes,
Table 19: Assessment by Monotherapy Products,
Table 20: Assessment by Combined Therapeutics,
Table 21: Assessment by Therapeutic Class,
Table 22: Assessment by Route of Administration,
Table 23: Assessment by Molecule Type,
Table 24: Assessment by Biologics/Non-Biologics,
Table 25: Discontinued Company Products

LIST OF FIGURES

Figure 1: Number of Products under Development,
Figure 2: Myasthenia Gravis Products under Development – Comparative Analysis,
Figure 3: Products under Development by Companies,
Figure 4: Products under Investigation by Universities/Institutes,
Figure 5: Late Clinical Stage Products,
Figure 6: Mid Clinical Stage Products,
Figure 7: Early Clinical Stage Products,
Figure 8: Pre-clinical and Discovery Stage Products,
Figure 9: Assessment by Monotherapy Products,
Figure 10: Assessment by Combined Therapeutics,
Figure 11: Comparative Analysis - Monotherapy and Combined Therapeutics,
Figure 12: Assessment by Therapeutic Class,
Figure 13: Assessment by Stage and Therapeutic Class,
Figure 14: Assessment by Route of Administration,
Figure 15: Assessment by Stage and Route of Administration,
Figure 16: Assessment by Molecule Type,
Figure 17: Assessment by Stage and Molecule Type,
Figure 18: Assessment by Biologics/Non-Biologics,
Myasthenia Gravis - Pipeline Review, Q2 2011 US$ 500.00 May, 2011 · 51 pages
Myasthenia Gravis - Pipeline Review, H2 2013 US$ 2,000.00 Dec, 2013 · 98 pages
Myasthenia Gravis Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 76 pages

Ask Your Question

Myasthenia Gravis - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: